See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research Article
Yu Kun Luo
Department of Ultrasound, First Medical Center, General Hospital of Chinese PLA
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Treatment for radioiodine refractory differentiated thyroid carcinoma (RR-DTC) is challenging. The purpose of this study was to assess the efficacy and safety of ultrasound-guided implantation of radioactive 125I-seed in radioiodine refractory differentiated thyroid carcinoma.
Methods: 36 cervical metastatic lymph nodes (CMLNs) diagnosed as RR-DTC from 18 patients were enrolled in this retrospective study. US and contrast-enhanced ultrasound (CEUS) examinations were performed before implantation. Follow-up consisted of US, CEUS, thyroglobulin (Tg) level and routine hematology at 1-3, 6, 9 and 12 months and every 6 months thereafter. The volumes of the nodules were compared before implantation and at each follow-up point. The volume reduction rate (VRR) of nodules was also recorded.
Results: The median volume of the nodules was 522.8 mm3 (147.5, 2009.6mm3) initially, which decreased significantly to 53.0mm3 (0, 285.7mm3) (P < 0.01) at the follow-up point of 24 months with a mean VRR as 87.4±18.1% (the range was 32–100%). During the follow-up period (the range was 24–50 months), 25 (69%) nodules had VRR greater than 90%, of which 12 (33%) nodules had VVR≈100% with structures unclear and only 125I seeds images visible. At the last follow-up visit, the serum Tg level decreased from 57.0 (8.6, 114.8) ng/ml to 4.9 (0.7, 50.3) ng/ml, (P < 0.01).
Conclusion: US-guided 125I seed implantation is safety and efficacy in treating RR- DTC. It could be an effective supplement for the comprehensive treatment of thyroid cancer.
Keywords
Differentiated thyroid carcinoma, Lymph node metastasis, Ultrasound, Iodine-125, Brachytherapy
Figure 1
Figure 2
Figure 3
No competing interests reported.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
Version 1
Posted 24 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 16 Apr, 2021
Reviews received
Received 24 Mar, 2021
Reviewers agreed
On 23 Mar, 2021
Reviewers invited
Invitations sent on 23 Mar, 2021
Editor assigned
On 23 Mar, 2021
Editor invited
On 23 Mar, 2021
Submission checks complete
On 23 Mar, 2021
First submitted
On 14 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Oncology
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Yu Kun Luo
Department of Ultrasound, First Medical Center, General Hospital of Chinese PLA
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
Version 1
Posted 24 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 16 Apr, 2021
Reviews received
Received 24 Mar, 2021
Reviewers agreed
On 23 Mar, 2021
Reviewers invited
Invitations sent on 23 Mar, 2021
Editor assigned
On 23 Mar, 2021
Editor invited
On 23 Mar, 2021
Submission checks complete
On 23 Mar, 2021
First submitted
On 14 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Oncology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Cancer.
Background: Treatment for radioiodine refractory differentiated thyroid carcinoma (RR-DTC) is challenging. The purpose of this study was to assess the efficacy and safety of ultrasound-guided implantation of radioactive 125I-seed in radioiodine refractory differentiated thyroid carcinoma.
Methods: 36 cervical metastatic lymph nodes (CMLNs) diagnosed as RR-DTC from 18 patients were enrolled in this retrospective study. US and contrast-enhanced ultrasound (CEUS) examinations were performed before implantation. Follow-up consisted of US, CEUS, thyroglobulin (Tg) level and routine hematology at 1-3, 6, 9 and 12 months and every 6 months thereafter. The volumes of the nodules were compared before implantation and at each follow-up point. The volume reduction rate (VRR) of nodules was also recorded.
Results: The median volume of the nodules was 522.8 mm3 (147.5, 2009.6mm3) initially, which decreased significantly to 53.0mm3 (0, 285.7mm3) (P < 0.01) at the follow-up point of 24 months with a mean VRR as 87.4±18.1% (the range was 32–100%). During the follow-up period (the range was 24–50 months), 25 (69%) nodules had VRR greater than 90%, of which 12 (33%) nodules had VVR≈100% with structures unclear and only 125I seeds images visible. At the last follow-up visit, the serum Tg level decreased from 57.0 (8.6, 114.8) ng/ml to 4.9 (0.7, 50.3) ng/ml, (P < 0.01).
Conclusion: US-guided 125I seed implantation is safety and efficacy in treating RR- DTC. It could be an effective supplement for the comprehensive treatment of thyroid cancer.
Figure 1
Figure 2
Figure 3
No competing interests reported.
Loading...